FDA Nominee Heidi Overton Faces Uncertain Committee Vote as White House Weighs Options, Report Says

Archive view of FDA Building 64 in Silver Spring, Maryland, in November 2010.
URL has been copied successfully!

Archive: FDA Building 64 in Silver Spring, Maryland, November 9, 2010. U.S. Food and Drug Administration / Wikimedia Commons, public-domain government work; cropped and resized. Agency context, not the nomination proceedings.

Some Trump administration officials are discussing whether to bolster Heidi Overton’s nomination to lead the Food and Drug Administration or abandon it, according to a Washington Post report published Monday, November 16, and carried by The Seattle Times. The report describes internal deliberations, not a decision to withdraw her nomination.

The Senate Health, Education, Labor and Pensions Committee lists a nominations meeting for Wednesday, November 18, at 9:45 a.m. Eastern. The committee’s announcement includes a vote on Overton. That is a scheduled committee vote, not Senate confirmation or a vote that has already happened.

The Post based its account of the White House discussions on four people familiar with the matter who spoke anonymously about a personnel issue. Two people told the newspaper that officials had begun discussing potential alternative candidates. The report did not establish that a replacement had been selected or a new nomination announced.

The White House did not immediately comment to the Post. A White House social-media account shared a column supporting Overton’s confirmation on Monday, the newspaper reported. That reported public support is distinct from the anonymous accounts of internal debate.

Committee Chairman Bill Cassidy, a Louisiana Republican, said in a CBS “Face the Nation” interview on Sunday, November 15, that he remained uncertain about the outcome. “I still have questions, and so I cannot tell you the outcome of that vote right now,” he said.

Cassidy also described weighing the drawbacks of successive temporary FDA leaders against confirming a permanent commissioner who might have some independence. His remarks were made Sunday, not after a committee decision on Overton.

For healthcare and life-sciences businesses following the agency’s leadership, the next scheduled step is the committee vote. The reported White House deliberations do not themselves change FDA rules, establish a withdrawal or determine the nomination’s outcome.

JBizNews Desk | Health

© JBizNews.com. All rights reserved. Unauthorized reproduction or redistribution is strictly prohibited.

Share this story:
Share on Facebook
Share by Email
X (Twitter)
Follow Me
Tweet
Whatsapp
LinkedIn
Copy link